Contraindications and Side Effects Mounjaro (tirzepatide) medications should not be used in individuals with: Medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2) Known hypersensitivity to tirzepatide or any components in the formulation According to clinical data, the most common side effects of Mounjaro include: Nausea Diarrhea Decreased appetite Vomiting Constipation Indigestion Abdominal discomfort Providers should discuss the risk of thyroid C-cell tumors with patients, although this remains a rare concern based on preclinical models
Clean the area with the alcohol swab, using gentle outward circles about the size of a silver dollar
FDA-approved versions of these medications have demonstrated impressive results in clinical studies, but tirzepatide may produce slightly greater weight loss due to its dual-hormone activation
Serious adverse events were balanced across groups
Aetna generally will not approve Zepbound alongside another GLP-1 receptor agonist such as semaglutide (Ozempic, Wegovy) or liraglutide (Saxenda)
It selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1
